澳大利亚暂停遗传学和人寿保险:与议会关于遗传歧视的建议相比,评估政策。

IF 2.5 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Public Health Research & Practice Pub Date : 2022-12-13 DOI:10.17061/phrp3242235
Jane Tiller, Paul Lacaze, Margaret Otlowski
{"title":"澳大利亚暂停遗传学和人寿保险:与议会关于遗传歧视的建议相比,评估政策。","authors":"Jane Tiller,&nbsp;Paul Lacaze,&nbsp;Margaret Otlowski","doi":"10.17061/phrp3242235","DOIUrl":null,"url":null,"abstract":"<p><p>Objectives and importance of study: Genetic discrimination is a health policy issue of international concern to clinicians, patients, researchers, and policy makers, and threatens the success of genomic medicine. In Australia, genetic discrimination in life insurance is legal and leads to public health harms, including deterring at-risk individuals from clinically indicated testing. In 2018, a Parliamentary Joint Committee recommended an urgent ban on the use of predictive genetic test results in life insurance underwriting in Australia, to be implemented in a form similar to the UK Code on genetic testing and life insurance. In 2019, the insurance industry, through the Financial Services Council (FSC), introduced a self-regulated moratorium that applies until 2024, but only to life insurance policies up to certain financial limits. The FSC moratorium will be reviewed in late 2022, but has no government oversight.</p><p><strong>Study type: </strong>Policy implementation evaluation Methods: We used policy evaluation methods to 1) summarise the key recommendations of the 2018 Parliamentary Committee that are directed towards practical aspects of policy development and content; and 2) assess the level of disparity between the implemented moratorium and the recommendations of the Committee.</p><p><strong>Results: </strong>There is a substantial disparity between the Australian moratorium and the Parliamentary Committee recommendations across key areas, including addressing self-regulation, co-development of policy, protection of tests taken during its term, and similarity with the UK Code. The FSC moratorium offers less protection to consumers than the UK Code on a number of measures, including the level of financial coverage, the involvement of government, certainty provided to individuals who have genetic testing, and the treatment of research results.</p><p><strong>Conclusions: </strong>The FSC moratorium is a step forward for Australia, but falls short of the Parliamentary recommendations. Further regulation by the Australian Government may be required to achieve the aims of the Parliamentary recommendations and ensure the intended level of consumer protection.</p>","PeriodicalId":45898,"journal":{"name":"Public Health Research & Practice","volume":"32 4","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2022-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The Australian moratorium on genetics and life insurance: evaluating policy compared to Parliamentary recommendations regarding genetic discrimination.\",\"authors\":\"Jane Tiller,&nbsp;Paul Lacaze,&nbsp;Margaret Otlowski\",\"doi\":\"10.17061/phrp3242235\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Objectives and importance of study: Genetic discrimination is a health policy issue of international concern to clinicians, patients, researchers, and policy makers, and threatens the success of genomic medicine. In Australia, genetic discrimination in life insurance is legal and leads to public health harms, including deterring at-risk individuals from clinically indicated testing. In 2018, a Parliamentary Joint Committee recommended an urgent ban on the use of predictive genetic test results in life insurance underwriting in Australia, to be implemented in a form similar to the UK Code on genetic testing and life insurance. In 2019, the insurance industry, through the Financial Services Council (FSC), introduced a self-regulated moratorium that applies until 2024, but only to life insurance policies up to certain financial limits. The FSC moratorium will be reviewed in late 2022, but has no government oversight.</p><p><strong>Study type: </strong>Policy implementation evaluation Methods: We used policy evaluation methods to 1) summarise the key recommendations of the 2018 Parliamentary Committee that are directed towards practical aspects of policy development and content; and 2) assess the level of disparity between the implemented moratorium and the recommendations of the Committee.</p><p><strong>Results: </strong>There is a substantial disparity between the Australian moratorium and the Parliamentary Committee recommendations across key areas, including addressing self-regulation, co-development of policy, protection of tests taken during its term, and similarity with the UK Code. The FSC moratorium offers less protection to consumers than the UK Code on a number of measures, including the level of financial coverage, the involvement of government, certainty provided to individuals who have genetic testing, and the treatment of research results.</p><p><strong>Conclusions: </strong>The FSC moratorium is a step forward for Australia, but falls short of the Parliamentary recommendations. Further regulation by the Australian Government may be required to achieve the aims of the Parliamentary recommendations and ensure the intended level of consumer protection.</p>\",\"PeriodicalId\":45898,\"journal\":{\"name\":\"Public Health Research & Practice\",\"volume\":\"32 4\",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2022-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Public Health Research & Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17061/phrp3242235\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Public Health Research & Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17061/phrp3242235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 1

摘要

研究目的和重要性:基因歧视是临床医生、患者、研究人员和决策者关注的国际卫生政策问题,威胁着基因组医学的成功。在澳大利亚,人寿保险中的基因歧视是合法的,会对公众健康造成危害,包括阻止有风险的个人进行临床指示的检测。2018年,议会联合委员会建议紧急禁止在澳大利亚人寿保险承保中使用预测性基因检测结果,并以类似于英国基因检测和人寿保险法典的形式实施。2019年,保险业通过金融服务委员会(FSC)推出了一项自我监管的暂停令,有效期至2024年,但仅适用于达到一定财务限制的人寿保险单。FSC的暂停将在2022年底进行审查,但没有政府监督。研究类型:政策实施评估方法:我们使用政策评估方法来1)总结2018年议会委员会针对政策制定和内容的实际方面的关键建议;及2)评估已实施的暂停兴建计划与委员会的建议之间的差异程度。结果:澳大利亚的暂停与议会委员会的建议在关键领域存在巨大差异,包括解决自我监管、共同制定政策、保护在其任期内进行的测试,以及与英国法典的相似性。与英国法典相比,FSC暂停对消费者提供的保护在一些措施上要少一些,包括财务覆盖水平、政府参与、为进行基因检测的个人提供的确定性,以及对研究结果的处理。结论:FSC的暂停是澳大利亚向前迈出的一步,但没有达到议会的建议。为了实现议会建议的目标和确保消费者保护的预期水平,可能需要澳大利亚政府进一步监管。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Australian moratorium on genetics and life insurance: evaluating policy compared to Parliamentary recommendations regarding genetic discrimination.

Objectives and importance of study: Genetic discrimination is a health policy issue of international concern to clinicians, patients, researchers, and policy makers, and threatens the success of genomic medicine. In Australia, genetic discrimination in life insurance is legal and leads to public health harms, including deterring at-risk individuals from clinically indicated testing. In 2018, a Parliamentary Joint Committee recommended an urgent ban on the use of predictive genetic test results in life insurance underwriting in Australia, to be implemented in a form similar to the UK Code on genetic testing and life insurance. In 2019, the insurance industry, through the Financial Services Council (FSC), introduced a self-regulated moratorium that applies until 2024, but only to life insurance policies up to certain financial limits. The FSC moratorium will be reviewed in late 2022, but has no government oversight.

Study type: Policy implementation evaluation Methods: We used policy evaluation methods to 1) summarise the key recommendations of the 2018 Parliamentary Committee that are directed towards practical aspects of policy development and content; and 2) assess the level of disparity between the implemented moratorium and the recommendations of the Committee.

Results: There is a substantial disparity between the Australian moratorium and the Parliamentary Committee recommendations across key areas, including addressing self-regulation, co-development of policy, protection of tests taken during its term, and similarity with the UK Code. The FSC moratorium offers less protection to consumers than the UK Code on a number of measures, including the level of financial coverage, the involvement of government, certainty provided to individuals who have genetic testing, and the treatment of research results.

Conclusions: The FSC moratorium is a step forward for Australia, but falls short of the Parliamentary recommendations. Further regulation by the Australian Government may be required to achieve the aims of the Parliamentary recommendations and ensure the intended level of consumer protection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Public Health Research & Practice
Public Health Research & Practice PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
6.70
自引率
0.00%
发文量
51
审稿时长
20 weeks
期刊介绍: Public Health Research & Practice is an open-access, quarterly, online journal with a strong focus on the connection between research, policy and practice. It publishes innovative, high-quality papers that inform public health policy and practice, paying particular attention to innovations, data and perspectives from policy and practice. The journal is published by the Sax Institute, a national leader in promoting the use of research evidence in health policy. Formerly known as The NSW Public Health Bulletin, the journal has a long history. It was published by the NSW Ministry of Health for nearly a quarter of a century. Responsibility for its publication transferred to the Sax Institute in 2014, and the journal receives guidance from an expert editorial board.
期刊最新文献
Aboriginal and Torres Strait Islander peoples' Quitline use and the Tackling Indigenous Smoking program. Co-designing policy with Aboriginal and Torres Strait Islander peoples: a protocol. Acceptability of an asymptomatic COVID-19 screening program for schools in Victoria, Australia: a qualitative study with caregivers from priority populations. UV arrows descend from above: lessons from a mass media campaign to improve sun protection behaviours among young adults. Are they the same? Disentangling the concepts of implementation science research and population scale-up.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1